Elevation of striatal interleukin-6 and serum corticosterone contents in MPTP-treated mice

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 9, 1999, Pages 680-683

  Kaku, Koichi ^a   Shikimi, Todahiro ^b   Kamisaki, Yoshinori ^d   Shinozuka, Kazumasa ^c   Ishino, Hiroshi ^d   Okunishi, Hideki ^b   Takaori, Shuji ^b  

^a SHIMANE UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^d NONE

Author keywords

Corticosterone; Interleukin 1 ; Interleukin 6; MPTP; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CORTICOSTERONE; DOPAMINE; INTERLEUKIN 1BETA; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CORTICOSTERONE BLOOD LEVEL; CYTOKINE RELEASE; DOPAMINERGIC SYSTEM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORTICOSTERONE; DOPAMINE AGENTS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; STRIATONIGRAL DEGENERATION;

EID: 0032836548     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.03113.x     Document Type: Article

References (34)

1. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl Acad. Sci. USA 1983; 80: 4546-50.
2. Heikkila RE, Hess A. Duvoisin RC. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984; 224: 1451-3.
3. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetra-hydropyridine by monoamine oxidase inhibitors. Nature 1984; 311: 467-9.
4. +, a metabolite of MPTP, by brain synaptosomes. Biochem. Biophys. Res. Commun. 1985; 128: 1228-32.
5. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl Acad. Sci. USA 1985; 82: 2173-7.
6. + administration to mice. Pharmacol. Toxicol. 1993; 72: 364-8.
7. + toxicity by deprenyl (selegiline). Ann. N.Y. Acad. Sci. 1994; 738: 214-21.
8. Kaltschmidt B, Baeuerle PA, Kaltschmidt C. Potential involvement of the transcription factor NF-κB in neurological disorders. Mol. Aspects Med. 1993; 14: 171-90.
9. Blackwell TS, Christman JW. The role of nuclear factor-κB in cytokine gene regulation. Am. J. Respir. Cell Mol. Biol. 1997; 17: 3-9.
10. Mogi M, Harada M, Kondo T et al. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from Parkinsonian patients. Neurosci. Lett. 1994; 180: 147-50.
11. Casolini P, Kabbaj M, Leprat F et al. Basal and stress-induced corti-costerone secretion is decreased by lesion of mesencephalie dopaminergic neurons. Brain Res. 1993; 622: 311-14.
12. Acun̄a-Castroviejo D, Coto-Montes A, Monti MG, Ortiz GG, Reiter RJ. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci. 1997; 60: PL23-9.
13. Jacobson L, Sapolsky R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary adrenal axis. Endocr. Rev. 1991; 12: 118-34.
14. Sandyk R, Iaconn RP, Kay SR. The hypothalamus in MPTP-induced Parkinsonism. Ital. J. Neutral. Sci. 1990; 11: 367-72.
15. O'Callaghan JP, Seidler FJ. 1-Methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP)-induced astrogliosis does not require activation of ornithine decarboxylase. Neurosci. Lett. 1992; 148: 105-8.
16. Arai N, Misugi K, Goshima Y, Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for Parkinsonism. Brain Res. 1990; 515: 57-63.
17. Date I, Felten DL, Felten SY. Long-term effect of MPTP in the mouse brain in relation to aging: Neurochemical and immunocytochemical analysis. Brain Res. 1990; 519: 266-76.
18. 3H]DOPA in various regions of the brain. J. Neurochem. 1966; 13: 655-69.
19. Takao Y, Kamisaki Y, Itoh T. β-Adrenergic regulation of amine precursor amino acid transport across the blood-brain barrier. Eur. J. Phatrmacol. 1992; 215: 245-51.
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951; 193: 265-75.
21. Bradford MM, Rapid and sensitive method for quantitation of micro-grain quantities of proteins utilizing principle of protein-dye binding. Anal. Biochem. 1976; 72:248-54.
22. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-́ levels are elevated in ventricular cerebrospinal fluid in juvenile Parkinsonism and Parkinson's disease. Neurosci. Lett. 1996; 211: 13-16.
23. Plata-Salamán CR. Immunoregulators in the nervous system. Neurosci. Biobehav. Rev. 1991; 15: 185-215.
24. O'Callaghan JP, Miller DB, Reinhard Jr JF, Characterization of the origins of astrocyte response to injury using the dopaminergic neuro-toxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. 1990; 521: 73-80.
25. Francis JW, Visger JV, Markelonis GJ, Oh TH. Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. Neurotoxicol. Teratol. 1995; 17: 7-12.
26. Kaku K, Shikimi T, Kamisaki Y et al. Nullification of a positive correlation between urinary contents of α1-microglobulin and ulinastatin with intracerebroventricularly administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium (MPP+) in mice. Psychopharmacology 1998; 136: 374-8.
27. + neurotoxicity in cultures of fetal rat dopaminergic neurons. Exp. Neurol. 1995; 136: 44-52.
28. Umegaki H, Yamada K, Naito M, Kameyama T, Iguchi A, Nabeshima T. Protective effect of interleukin-6 against the death of PCl2 cells caused by serum deprivation or by the addition of a calcium ionophore. Biochem. Pharmacol. 1996; 52: 911-16.
29. Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience 1991; 40; 445-52.
30. Kushima Y, Hama T, Hatanaka H. Interleukin-6 as a neurotrophic factor for promoting the survival of cultured catecholaminergic neurons in a chemically defined medium from fetal and postnatal rat midbrains. Neurosci. Res. 1992; 13: 267-80.
31. Mizobuchi M, Hineno T, Kakimoto Y, Hiratani K. Increase of plasma adrenocorticotrophin and cortisol in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated dogs. Brain Res. 1993; 612: 319-21.
32. Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I. Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: Ultradian secretory pulsatility and diurnal variation. Neurobiol. Aging 1997; 18: 285-9.
33. Bellomo G, Santambrogio L, Fiacconi M, Scarponi AM, Ciuffetti G. Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's disease. J. Neurol. 1991; 238: 19-22.
34. Shikimi T, Inagaki T, Kaku K, Ishino H, Okunishi H, Takaori S. Nullification of a positive correlation between urinary levels of α 1-microglobulin and ulinastatin by 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) in mice. Psychoneuroendocrinology 1997; 22: 269-75.